Literature DB >> 28210873

Inborn errors of metabolism associated with psychosis: literature review and case-control study using exome data from 5090 adult individuals.

Yannis J Trakadis1, Vanessa Fulginiti2, Mark Walterfang3,4.   

Abstract

A literature review was conducted, using the computerized "Online Mendelian Inheritance in Man" (OMIM) and PubMed, to identify inborn errors of metabolism (IEM) in which psychosis may be a predominant feature or the initial presenting symptom. Different combinations of the following keywords were searched using OMIM: "psychosis", "schizophrenia", or "hallucinations" and "metabolic", "inborn error of metabolism", "inborn errors of metabolism", "biochemical genetics", or "metabolic genetics". The OMIM search generated 126 OMIM entries, 40 of which were well known IEM. After removing IEM lacking evidence in PubMed for an association with psychosis, 29 OMIM entries were identified. Several of these IEM are treatable. They involve different small organelles (lysosomes, peroxisomes, mitochondria), iron or copper accumulation, as well as defects in other met-abolic pathways (e.g., defects leading to hyperammonemia or homocystinemia). A clinical checklist summarizing the key features of these conditions and a guide to clinical approach are provided. The genes corresponding to each of these con-ditions were identified. Whole exome data from 2545 adult cases with schizophrenia and 2545 unrelated controls, accessed via the Database of Genotypes and Phenotypes (dbGaP), were analyzed for rare functional variants in these genes. The odds ratio of having a rare functional variant in cases versus controls was calculated for each gene. Eight genes are significantly associated with schizophrenia (p < 0.05, OR >1) using an unselected group of adult patients with schizophrenia. Increased awareness of clinical clues for these IEM will optimize referrals and timely metabolic interventions.

Entities:  

Mesh:

Year:  2017        PMID: 28210873     DOI: 10.1007/s10545-017-0023-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  32 in total

1.  Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients.

Authors:  Orit Neudorfer; Gregory M Pastores; Bai J Zeng; John Gianutsos; Charles M Zaroff; Edwin H Kolodny
Journal:  Genet Med       Date:  2005-02       Impact factor: 8.822

2.  Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome.

Authors:  Catherine L Clelland; Laura L Read; Amanda N Baraldi; Corinne P Bart; Carrie A Pappas; Laura J Panek; Robert H Nadrich; James D Clelland
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

3.  Varied psychiatric manifestations of acute intermittent porphyria.

Authors:  P J Santosh; S Malhotra
Journal:  Biol Psychiatry       Date:  1994-12-01       Impact factor: 13.382

4.  [Adult-onset Hartnup disease presenting with neuropsychiatric symptoms but without skin lesions].

Authors:  E Mori; A Yamadori; A Tsutsumi; Y Kyotani
Journal:  Rinsho Shinkeigaku       Date:  1989-06

5.  Psychiatric symptoms and disorders in phenylketonuria.

Authors:  V L Brumm; D Bilder; S E Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

6.  Folate-responsive homocystinuria and "schizophrenia". A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity.

Authors:  J M Freeman; J D Finkelstein; S H Mudd
Journal:  N Engl J Med       Date:  1975-03-06       Impact factor: 91.245

7.  Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness.

Authors:  M H Abbott; S E Folstein; H Abbey; R E Pyeritz
Journal:  Am J Med Genet       Date:  1987-04

8.  Intermittent neurological symptoms in a girl with a maple syrup urine disease (MSUD) variant.

Authors:  G Holmgren; A Brundin; K H Gustavson; S Sjögren; W J Kleijer; M F Niermeijer
Journal:  Neuropediatrics       Date:  1980-11       Impact factor: 1.947

9.  Neuropsychological aspects of Wilson's disease.

Authors:  J K Rathbun
Journal:  Int J Neurosci       Date:  1996-04       Impact factor: 2.292

Review 10.  Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.

Authors:  Olivier Bonnot; Hans Hermann Klünemann; Frederic Sedel; Sylvie Tordjman; David Cohen; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

View more
  5 in total

1.  A new opportunity: metabolism and neuropsychiatric disorders.

Authors:  Tamas Kozicz; E Morava
Journal:  J Inherit Metab Dis       Date:  2018-07       Impact factor: 4.982

2.  Assessment of Potential Clinical Role for Exome Sequencing in Schizophrenia.

Authors:  Thivia Balakrishna; David Curtis
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

3.  Stress, Cortisol and NR3C1 in At-Risk Individuals for Psychosis: A Mendelian Randomization Study.

Authors:  Anton Iftimovici; Oussama Kebir; Qin He; Thérèse M Jay; Guy A Rouleau; Marie-Odile Krebs; Boris Chaumette
Journal:  Front Psychiatry       Date:  2020-07-10       Impact factor: 4.157

4.  Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision.

Authors:  Patrick Forny; Friederike Hörster; Diana Ballhausen; Anupam Chakrapani; Kimberly A Chapman; Carlo Dionisi-Vici; Marjorie Dixon; Sarah C Grünert; Stephanie Grunewald; Goknur Haliloglu; Michel Hochuli; Tomas Honzik; Daniela Karall; Diego Martinelli; Femke Molema; Jörn Oliver Sass; Sabine Scholl-Bürgi; Galit Tal; Monique Williams; Martina Huemer; Matthias R Baumgartner
Journal:  J Inherit Metab Dis       Date:  2021-03-09       Impact factor: 4.750

5.  Next-generation gene panel testing in adolescents and adults in a medical neuropsychiatric genetics clinic.

Authors:  Y Trakadis; A Accogli; B Qi; D Bloom; R Joober; E Levy; K Tabbane
Journal:  Neurogenetics       Date:  2021-08-07       Impact factor: 2.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.